Analogs of a superacidic NMDA receptor agonist, N-phthalamoyl-L-glutamic acid (PhGA): Activity and mode of interaction with the receptor recognition site

Neurophysiology

Volumn 31, Issue 5, 1999, Pages 295-303

  Zhenochin, S P ^b   Piotrovsky, L B ^a   Dumpis, M A ^a   Maximyuk, O P ^b   Lishko, P V ^b   Tsyndrenko, A Ya ^b   Krishtal, O A ^b  

^a BOGOMOLETZ INSTITUTE OF PHYSIOLOGY   (Ukraine)

^b INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; GLUTAMIC ACID DERIVATIVE; ISOPHTHALAMOYL GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; N PHTHALAMOYL GLUTAMIC ACID DERIVATIVE; TEREPHTHALAMOYL GLUTAMIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DRUG EFFECT; HIPPOCAMPUS; MEMBRANE CURRENT; MOLECULAR INTERACTION; MOLECULAR MODEL; MOLECULAR RECOGNITION; MOUSE; NERVE CELL; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

EID: 0033360848     PISSN: 00902977     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02515110     Document Type: Article

References (32)

1. C. Ikonomidou and L. Turski, "Neurodegenerative disorders: clues from glutamate and energy metabolism," Crit. Rev. Neurobiol., 10, 239-263 (1996).
2. B. S. Meldrum, "The role of glutamate in epilepsy and other CNS disorders," Neurology, 44, 14-23 (1994).
3. P. T. Francis, N. R. Sims, A. W. Procter, and D. Bowen, "Cortical pyramidal neurones loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives," J. Neurochem., 60, 1589-1604 (1993).
4. A. B. Young, J. T. Greenamyre, Z. Hollingsworth, et al., "NMDA receptor loses in putamen from patients with Huntington's disease," Science, 241, 981-983 (1988).
5. T. Klockgether and L. Turski, "Toward an understanding of the role of glutamate in experimental Parkinsonism: agonist-sensitive sites in the basal ganglia," Ann. Neurol., 34, 585-593 (1993).
6. S. A. Lipton, "HIV-related neuronal injury. Potential therapeutic intervention with calcium channel antagonists and NMDA antagonists," Mol. Neurobiol., 8, 181-196 (1994).
7. W. E. M•ller, G. Pergande, H. Ushijima, et al., "Neurotoxicity in rat cortical cells caused by N-methyl-D-aspartate (NMDA) and gp120 of HIV-1: induction and pharmacological intervention," Prog. Mol. Subcell. Biol., 16, 44-57 (1996).
8. A. Yu. Bespalov, M. A. Dumpis, L. B. Piotrovsky, and E. E. Zvartau, "Excitatory amino acid receptor antagonist kynurenic acid attenuates rewarding potential of morphine," Eur. J. Pharmacol., 264, 494-496 (1994).
9. M. E. Wolf and M. Jeziorski, "Coadiministration of MK-801 with amphetamine, cocaine or morphine prevents rather than transiently masks the development of behavioral sensitization," Brain Res., 613, 291-296 (1993).
10. G. P. Reynolds, "Development in the drug treatment of schizophrenia,"Trends Pharmacol. Sci., 13, 116-121 (1992).
11. J. Willets, R. L. Balster, and J. D. Leander, "The behavioral pharmacology of NMDA receptor antagonists," Trends Pharmacol. Sci., 11, 423-428 (1990).
12. B. Ebert, U. Madsen, K. K. Soby, and P. Krogsgaard-Larsen, "Functional partial agonism at ionotropic excitatory amino acid receptors," Neurochem. Int., 29, 309-316 (1996).
13. J. C. Watkins, P. Krogsgaard-Larsen, and T. Honore, "Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists," Trends Pharmacol. Sci., 11, 25-33 (1990).
14. J. C. Watkins, "Some chemical highlights in the development of excitatory amino acid pharmacology," Can. J. Physiol. Pharmacol., 69, 1064-1075 (1991).
15. J. J. Hansen and P. Krogsgaard-Larsen, "Structural, conformational, and stereochemical requirements of central excitatory amino acid receptors," Med. Res. Rev., 10, 55-94 (1991).
16. J. T. Coyle, R. Blakely, R. Zaczek, et al., "Acidic peptides in brain: do they act as putative glutamatergic synapses?," Adv. Exp. Med. Biol., 203, 375-384 (1986).
17. H. M. Valivullah, J. Lancaster, P. M. Sweetnam, and J. H. Neale, "Interactions between N-acetylaspartylglutamate and AMPA, kainate, and NMDA binding sites," J. Neurochem., 63, 1714-1716 (1994).
18. N. I. Kiskin, A. Ya. Tsyndrenko, M. A. Dumpis, et al., "A novel selective NMDA agonist. N-phthalamoyl-L-glutamic acid (PhGA)," NeuroReport, 2, 29-32 (1991).
19. O. N. Koreshonkov, P. V. Perestenko, M. A. Dumpis, and L. B. Piotrovsky, "The effect of N-phthalamoyl-L-glutamic acid (PhGA), a novel selective NMDA receptors agonist, on the binding of [3H]-L-Glu with the synaptic membranes of human hippocampus," Byull. Éksp. Biol. Med., 6, 563-565 (1992).
20. A. P. Garyaev, O. V. Kononov, M. A. Dumpis, and L. B. Piotrovsky, "The excitatory action on CNS of N-acyl derivatives of glutamic and aspartic acids," Khim.-Farm. Zh., 5, 20-25 (1990).
21. O. N. Koreshonkov, P. V. Perestenko, M. A. Dumpis, and L. B. Piotrovsky, "The interaction of structural analogues of N-phthalamoyl-L-glutamic acid with the synaptic membranes of human hippocampus," Khim.-Farm. Zh., 8, 6-8 (1995).
22. I. V. Chizhmakov, N. I. Kiskin, and O. A. Krishtal, "Two types of steady-state desensitization of N-methyl-D-aspartate receptor in isolated hippocampal neurones of rat," J. Physiol., 448, 453-472 (1992).
23. A. P. Garyaev, M. A. Dumpis, L. N. Poznyakova, et al., "Excitatory action of some aspartate- and glutamate-containing dipeptides after intracerebroventricular injection in mice," Eur. J. Pharmacol., 197, 157-160 (1991).
24. M. Saunders, "Stochastic exploration of molecular mechanics of energy surfaces. Hunting for the global minimum," J. Am. Chem. Soc., 109, 3150-3159 (1987).
25. U. Burkert and N. L. Allinger, Molecular Mechanics, Washington (1982).
26. D. Ortvine, T. Malone, C. F. Bigge, et al., "Generation of N-methyl-D-aspartate agonist and competitive antagonist pharmacophore model. Design and synthesis of phosphonoalkyl-substituted tetrahydroisoquinolines as novel antagonists," J. Med. Chem., 35, 1345-1370 (1992).
27. A. Dorville, I. McCort-Tranchepain, D. Vichard, et al., "Preferred antagonist binding state of the NMDA receptor: synthesis, pharmacology, and computer modelling of (phosphonomethyl)phenylalanine derivatives," J. Med. Chem., 35, 2551-2562 (1992).
28. Sybyl 5.3, Tripos Ass. Inc. (1989).
29. C. F. Bigge, C. Humblet, G. Johnson, et al., "Design, synthesis and molecular modelling of phosphoalkyltetrahydroisoquinolines as competitive NMDA antagonists," in: Trends in Medicinal Chemistry' 90. Blackwell, London (1992), pp. 153-160.
30. A. J. Hutchison M. Williams, C. Angst, et al., "4-(phosphoalkyl)- and 4-(phosphonoalkenyl)-2-piperidine carboxylic acids: synthesis, activity at N-methyl-D-aspartic receptors, and anticonvulsant activity," J. Med. Chem., 32, 2171-2178 (1989).
31. J. C. Watkins and H. J. Olverman, "Agonists and antagonists for excitatory amino acid receptors," Trends Neurosci., 10, 265-272 (1987).
32. G. E. Fagg, J. Baud, R. Hall, and J. Dindwall, "Do agonists and competitive antagonists hind to distinct sites of the NMDA receptors?," in: Frontiers in Excitatory Amino Acid Research, Alan R. Liss (1988), pp. 59-66.